Accelerated Approval Remains “Viable Pathway,” FDA’s Woodcock Says
By
Sue Sutter / Email the Author / “The Pink Sheet” Jun. 27, 2011, Vol. 73, No. 26
Regulatory Update / Word Count: 1283 / Article # 00110627003
Executive Summary
FDA’s accelerated approval program is alive and well now, and will remain a viable pathway in the future, despite concerns within the industry and investor communities that recent oncology regulatory actions are hastening the program’s demise.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.